A new study has revealed that blood-based diagnostic tests can accurately calculate in 70% of females experiencing high risk of preterm labor chances of whether or not they will give premature births.
Professor Stephen Lye from the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada, said in a news release that a lot of TPTL women are unnecessarily hospitalized. He added that they want to come up with a test that can distinguish true and false labor such that women in true labor can get the right medical care while those in false labor receive supportive care without hospitalization.
These recent findings will play significant role as pre-term birth ranks as one of the main causes of infant mortality across the globe. Study reveals that one in every 20 women becomes hospitalized with signs of premature labor and gives birth prematurely within ten days.
According to researchers, the current preterm labor diagnostic evaluation referred to as fetal fibronectin (fFN) test is easily affected by some factors which can trigger false positives, whereas very few women go for the fFN testing.
In their struggle to come up with a diagnostic test that can be used by all women, researchers made use of microarrays to study various whole blood gene expression linked with spontaneous premature birth within 48 hours in women admitted to hospital experiencing signs of premature labor, which is a crucial time window to stall and avert premature birth.
The current discovery has shed light on the knowledge about a set of nine genes and clinical blood data extensively predicted whether 70% of participants would not express signs of spontaneous preterm birth within 48 hours of their stay at the hospital.
Additionally, the research also indicated that data from the nine genes along clinical blood data were significantly more precise than the current standardized fFN test.
The findings were made public on May 14, 2014 in the open access journal PLOSE ONE.